GLUE 8-K 2026-11-05

Monte Rosa Therapeutics, Inc. (GLUE) 8-K dated 2026-11-05 — accession 0001193125-26-448527.

Monte Rosa Therapeutics, Inc. (GLUE) is a biotechnology company listed on NASDAQ.

Monte Rosa Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001193125-26-448527.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported GLUE revenue for 2025-12-31 was $123.7M. Net income was -$38.6M. Revenue was up 63.5% from 2024-12-31 to 2025-12-31. GLUE currently screens at market cap $1.56B.

Not investment advice. The GLUE SEC hub lists recent forms. The stock page is the research view.